At MeMed, a leader in host response technologies, we decode the body’s complex signals into simple insights that improve people’s lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas. We have developed the FDA-cleared, point-of-need, rapid measurement platform called MeMed Key® to ensure timely availability of these novel tests during the clinician’s decision-making workflow.
Our lead product, the FDA-cleared MeMed BV®, accurately differentiates bacterial from viral infection, enabling improved patient management, including appropriate antibiotic use, helping address the global healthcare challenge of antimicrobial resistance. Based on computational integration of bacterial and viral-responsive immune proteins, MeMed Key delivers the MeMed BV test results in 15 minutes from serum and was clinically validated on thousands of patients.
MeMed’s international team exemplifies bio-convergence, encompassing experts in molecular immunology, bioinformatics, assay development, engineering, and infectious disease.
Brands: MeMed